ITEM 4. INFORMATION ON THE COMPANY
|A.||History and Development of the Company
We are a Swiss stock corporation (société
anonyme) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (société
à responsabilité limitée) on February 13, 2003 with our registered office and domicile in Basel,
Switzerland. We converted to a Swiss stock corporation (société anonyme) under the laws of Switzerland on
August 25, 2003. Out Swiss enterprise identification number is CHE-109.878.825. Our domicile and registered office is in Ecublens,
at EPFL Innovation Park Building B, 1015 Lausanne, Vaud, Switzerland. Our ordinary shares were admitted to trading on Nasdaq Global
Market on September 23, 2016. Our shares are traded under the symbol ACIU.
Our registered and principal executive
offices are located in Ecublens, at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, our general telephone number
is (41) 21 345 91 21 and our internet address is www.acimmune.com. Our website and the information contained on or accessible through
our website are not part of this document.
We are a clinical stage biopharmaceutical
company focused on neurodegenerative diseases with five product candidates in clinical trials. We leverage our two proprietary
technology platforms to discover, design and develop novel, proprietary small molecules, antibodies and vaccines for prevention,
diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized
as the leading cause of neurodegenerative diseases, such as Alzheimer’s disease, or AD, and Parkinson’s disease, or
PD, with common mechanisms and drug targets, such as Abeta, Tau, alpha-synuclein and Tar DNA-binding Protein (TDP-43). We believe
that our large and diverse pipeline of nine therapeutic candidates and three diagnostic candidates has the potential to drive a
paradigm shift in the treatment of a broad spectrum of neurodegenerative and other diseases related to protein misfolding.
A summary of the business highlights in
2018 is provided in the graph below:
The diagram in Figure 2 below summarizes
the status of our research and development programs.